Education
About Us
Working with TipRanks
Follow Us
Brii Biosciences Limited (HK:2137)
:2137
RESEARCH TOOLSreports
2137 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.80 - HK$3.09
Previous CloseN/A
Volume2.92M
Average Volume (3M)6.09M
Market Cap
HK$1.52B
Enterprise Value-HK$1.86B
Total Cash (Recent Filing)HK$2.33B
Total Debt (Recent Filing)HK$28.02M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 20, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding732,100,900
10 Day Avg. Volume8,281,265
30 Day Avg. Volume6,092,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$0.80 and its highest was HK$3.09 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$1.52B.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2025 which is in 11 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 21, 2025. The company reported -HK$0.339 earnings per share for the quarter, missing the consensus estimate of -HK$0.251 by -HK$0.087.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate is -0.3.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 732,100,900 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.339 in its last earnings report, missing expectations of -HK$0.251. Following the earnings report the stock price went up 6.273%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
Company Description
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
3D Medicines, Inc.
―
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Hightide Therapeutics Inc
―
Ownership Overview
―
Insiders
0.05%
Mutual Funds
― Other Institutional Investors
99.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---